Author

Tina Albertson

Observed names: Albertson, Tina, T. Albertson, Tina M Albertson, Tina M. Albertson, Tina Marie Albertson

Institution: Caribou Biosciences (United States)

Observed institutions: Albert Einstein College of Medicine, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, University of Oregon, University of Washington, Bristol-Myers Squibb (United States), Lyell Immunopharma (United States), Caribou Biosciences (United States), Juno Therapeutics (United States), Seagen (United States)

OpenAlex ID: A5021947426

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

2020 · Jeremy S Abramson, M Lia Palomba, et al. · The Lancet · 2,421

EARLY FLOWERING3 Encodes a Novel Protein That Regulates Circadian Clock Function and Flowering in Arabidopsis

2001 · Karen A. Hicks, Tina M. Albertson, et al. · The Plant Cell · 310

DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice

2009 · Tina M. Albertson, Masanori Ogawa, et al. · Proceedings of the National Academy of Sciences · 236

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

2017 · Jeremy S. Abramson, Brianne McGree, et al. · New England Journal of Medicine · 206

PDF

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

2018 · Jeremy S. Abramson, Leo I. Gordon, et al. · Journal of Clinical Oncology · 166

DNA replication fidelity and cancer

2010 · Bradley D. Preston, Tina M. Albertson, et al. · Seminars in Cancer Biology · 163

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

2019 · Jeremy S. Abramson, Maria Lia Palomba, et al. · Blood · 116

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

2017 · Jeremy S. Abramson, Maria Lia Palomba, et al. · Blood · 62

2021 · Sophie Snyder, Tina Albertson, et al. · Advances in Therapy · 34

PDF

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2016 · Jeremy S. Abramson, Lia Palomba, et al. · Blood · 32

High Cr Rates in Relapsed/refractory (r/r) Aggressive B‐nhl Treated With the Cd19‐directed Car T Cell Product Jcar017 (transcend Nhl 001)

2017 · J. Abramson, M.L. Palomba, et al. · Hematological Oncology · 31

PDF

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

2014 · Amir T Fathi, Robert Chen, et al. · Blood · 28

High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

2018 · Jeremy S. Abramson, Tanya Siddiqi, et al. · Journal of Clinical Oncology · 27

CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

2017 · Jeremy S. Abramson, Maria Lia Palomba, et al. · Journal of Clinical Oncology · 27

Case Series

2010 · Piper M. Treuting, Tina M. Albertson, et al. · Toxicologic Pathology · 21

PDF

DNA Replication Fidelity: Proofreading in Trans

2006 · Tina M. Albertson, Bradley D. Preston · Current Biology · 21

PDF

EARLY FLOWERING3 Encodes a Novel Protein That Regulates Circadian Clock Function and Flowering in Arabidopsis

2001 · Karen A. Hicks, Tina M. Albertson, et al. · The Plant Cell · 21

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

2019 · Jeffrey Teoh, Timothy G. Johnstone, et al. · Blood · 18

JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL

2017 · Christopher G. Ramsborg, Paul Guptill, et al. · Blood · 18

CD30 expression in nonlymphomatous malignancies.

2012 · Jeff Porter Sharman, Jerome H. Goldschmidt, et al. · Journal of Clinical Oncology · 16

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

2013 · Uma Borate, Amir T. Fathi, et al. · Blood · 15

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

2017 · Tanya Siddiqi, Jeremy S. Abramson, et al. · Blood · 14

Divergent cellular phenotypes of human and mouse cells lacking the Werner syndrome RecQ helicase

2009 · Kiranjit K. Dhillon, Julia M. Sidorova, et al. · DNA repair · 14

Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).

2018 · Tanya Siddiqi, Jeremy S. Abramson, et al. · Journal of Clinical Oncology · 13

Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).

2014 · Andres Forero-Torres, Craig Moskowitz, et al. · Journal of Clinical Oncology · 12

Works count: 46

Citation count: 4,110

H-index: 18

I10-index: 28